Core Capital Management & Research, inc.’s Bristol-Myers Squibb BMY Stock Holding History

Core Capital Management & Research, inc.’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.5M	Buy	+82,074	New	+$4.71M	2.89%	12

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Core Capital Management & Research, inc.'s BMY Position: Q2 2026 in Review

Core Capital Management & Research, inc. opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 82,074 shares worth $5.5M. The stake represents 2.89% of the portfolio and ranks #12 among its holdings.

2,519 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Core Capital Management & Research, inc. held 82,074 shares of Bristol-Myers Squibb worth $5.5M as of Q2 2026.
Bristol-Myers Squibb was a new Core Capital Management & Research, inc. position in Q2 2026.
Bristol-Myers Squibb made up 2.89% of Core Capital Management & Research, inc.'s portfolio in Q2 2026, its #12 holding.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Core Capital Management & Research, inc.'s 13F filing for Q2 2026, filed 9 Sep 2026.